- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Fund Finance
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- Innovation Protection
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Innovation Protection
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy Transition
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- Artificial Intelligence (AI) and Machine Learning
- Buy American
- Crisis Management
- Doing Business in Latin America
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Institutional Culture and Sensitive Investigations
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Events 212 results
Webinar
May 8, 2025
Fraud Enforcement in the Trump Administration and Strategies to Mitigate Risk
Conference
May 1, 2025
Annual California Life Sciences Summit
Webinar
April 10, 2025
Combination, Personalized, and Advanced Therapy Medicinal Products
Webinar
March 20, 2025
Regulatory Exclusivities
Speaking Engagement
February 27, 2025
Dale Giali to Speak at the 2025 Consumer Packaged Goods (CPG) Legal Forum
Webinar
February 20, 2025
Orphan and Pediatric Medicinal Products
Webinar
February 13, 2025
Impact of the 2024 Election on Pharmaceutical, Biologics and Device Manufacturers
Webinar
January 29, 2025
Summary of FDA’s New Final Guidance: Scientific Information on Unapproved Uses
Webinar
January 28, 2025
Overpayments, Internal Investigations and FCA Updates: What Providers Need to Know for Continued Compliance in 2025
Webinar
January 22, 2025
Year in Review for Drug and Device Advertising and Promotion
Webinar
January 16, 2025
Steps Before Marketing Authorization (MA)
Speaking Engagement
January 6, 2025
Nikki Reeves to Speak at Inaugural Episode of FDAWatch